+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
JAGSNPHARM

Jagsonpal Pharmaceuticals Share Price

₹231.21 -6.84 (-2.87%)
49.17% Gain from 52W Low

07 Aug, 2026 3:53 PM (IST)

Jagsonpal Pharmaceuticals live price: ₹231.21. It opened at ₹240 vs previous close ₹238; intraday high/low: ₹240/₹229. The 50 & 200 DMA stand at ₹223.20/₹210.00.

Jagsonpal Pharmaceuticals Performance

  • Today's Low
  • ₹229
  • Today's High
  • ₹240
  • 52 Week Low
  • ₹155
  • 52 Week High
  • ₹269
  • Open Price₹240
  • Previous Close₹238
  • Volume74,930
  • 50 DMA₹223.20
  • 100 DMA₹214.50
  • 200 DMA₹210.00

Jagsonpal Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -3.15%
  • Over 3 Month + 8.03%
  • Over 6 Month + 37.49%
  • Over 1 Year -13.76%

Smart Investing Starts Here Start SIP with Jagsonpal Pharmaceuticals for Steady Growth!

Invest Now

Jagsonpal Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 33.5
  • PEG Ratio
  • -1.3
  • Market Cap Cr
  • 1,524
  • P/B Ratio
  • 5.5
  • Average True Range
  • 10.8
  • EPS
  • 6.9
  • Dividend Yield
  • 1.1
  • MACD Signal
  • 3.4
  • RSI
  • 52.5
  • MFI
  • 94.54

Latest Stock News Updates

Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earning Call Transcript for meeting held on July 30, 2026

Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30, 2026 at 2:30 P.M.

Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2026

Jagsonpal Pharmaceuticals Financials

Jagsonpal Pharmaceuticals Technicals

EMA & SMA

Current Price
₹231.21
-6.84 (-2.87%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹230.40
  • 50 Day
  • ₹223.20
  • 100 Day
  • ₹214.50
  • 200 Day
  • ₹210.00

Resistance and Support

233.3 Pivot Speed
  • R3 248.30
  • R2 244.00
  • R1 237.60
  • S1 226.90
  • S2 222.60
  • S3 216.20

Jagsonpal Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-29 Quarterly Results
2026-04-27 Audited Results & Final Dividend
2026-03-12 Buy Back of Shares
2026-01-21 Quarterly Results
2025-11-03 Quarterly Results
Date Purpose Remarks
2025-09-12 FINAL Rs.2.50 per share(125%)Final Dividend
2024-09-06 FINAL Rs.5.00 per share(100%)Final Dividend
2023-08-21 FINAL Rs.5.00 per share(100%)Dividend
2021-11-01 INTERIM Rs.4.00 per share(80%)Interim Dividend
View Jagsonpal Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2025-01-08 Split Stock split from Rs. 5/- to Rs. 2/-.
2004-07-28 Split Subdivision of equity shares from Rs. 10/- to Rs. 5/-

Jagsonpal Pharmaceuticals Shareholding Pattern

69.05%
28.04%
2.3%
0.62%

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. View More
  • NSE Symbol
  • JAGSNPHARM
  • BSE Symbol
  • 507789
  • ISIN
  • INE048B01035

Similar Stocks to Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals FAQs

Jagsonpal Pharmaceuticals share price is ₹231 As on 08 August, 2026 | 22:16

The Market Cap of Jagsonpal Pharmaceuticals is ₹1524.4 Cr As on 08 August, 2026 | 22:16

The P/E ratio of Jagsonpal Pharmaceuticals is 33.5 As on 08 August, 2026 | 22:16

The PB ratio of Jagsonpal Pharmaceuticals is 5.5 As on 08 August, 2026 | 22:16

The 52 week High & Low of Jagsonpal Pharmaceuticals is ₹269.2/₹155 respectively As on 08 August, 2026 | 22:16

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23